Garcia-Melendo, C, Morales-Munera, CE, Dalmau, J, Cubiro, X, Lopez-Sanchez, C, Mozos, A, Yelamos, O. Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma. Dermatologic Therapy. 2022; 35(5)DOI:10.1111/dth.15388. PMID:35174945. IF:3.600(Q1/3D).

Reich, K, Conrad, C, Kristensen, LE, Smith, SD, Puig, L, Rich, P, Sapin, C, Holzkaemper, T, Koppelhus, U, Schuster, C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(3)DOI:10.1080/09546634.2021.1892024. PMID:33641593. IF:2.900(Q2/4D).

Iznardo, H, Bredrup, C, Bernal, S, Gladkauskas, T, Mascaro, JM, Roe, E, Baselga, E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4)DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2.000(Q3/8D).

del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Ruiz-Villaverde, R, Llamas-Velasco, MD, Rocamora, V, Julia, M, Notario, J, Fernandez-Freire, LR, Sahuquillo-Torralba, A, Vidal, D, Rivera, R, Carretero, G, Mateu, A, de la Cueva, P, Carrascosa, JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 2022; 35(2)DOI:10.1111/dth.15231. PMID:34820971. IF:3.600(Q1/3D).